Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-05-09
2006-05-09
Jones, Dwayne C. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S211100, C514S211110, C514S211120
Reexamination Certificate
active
07041661
ABSTRACT:
The invention relates to the use of compound of Formula I in treating patients for inflammatory or neuropathic pain as well as various symptoms of multiple sclerosis
REFERENCES:
patent: 5008280 (1991-04-01), Gueremy et al.
patent: 6369221 (2002-04-01), Hardy et al.
patent: 0374040 (1993-03-01), None
patent: WO99/05147 (1999-02-01), None
patent: WO02100880 (2002-12-01), None
Gilgun-Sherki et al, Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis, Brain Res., Vo. 989, No. 2, Nov., 2003, pp196-204.
Matute C, Characteristics of acute and chronic kainate excitotoxic damage to the optic nerve, Proceedings of the National Academy of Sciences of USA, National Academy of Science, Washington, U.S., vol. 95, No. 17, Aug. 1998, pp 10229-10234.
Matute et al, The link between excitotoxid oligodendroglial death and demyelinating diseases, Trends in Neuroscience, Apr. 2001, pp 224-230.
Adams, R. A. et al, Multiple Sclerosis and Allied Demyelinative Diseases, Principles of Neurology, 6th Edition, 1997, pp 902-927.
Bagetta G et al, Prevention by the NMDA receptor antagonist, MK801 of neuronal loss produced by tetanus toxin in the rat hippocampus, Br. J. Pharmacology, vol. 101, 1990, pp 776-780.
Dickenson A. H. et al, Antagonism at the glycine site on the NMDA receptor reduces spinal nociception in the rat, Neurosc. Letters vol. 121, 1991, pp 263-266.
Hauser S. L. et al, Multiple Sclerosis and Other Demyelinating Diseases, Harrison's Principles of Internal Medicine, 14th Edition, vol. 2, 1998, pp 1409-1419.
Kehne J. H. et al, NMDA receptor complex antagonists have potential anxiolytic effects as measured with separation-induced ultrasonic vocalizations, European Journal of Pharmacology, vol. 193, (1991), pp 283-292.
Lipton,S. A. et al, Synergistic Effects of HIV Coat Protein and NMDA Receptor—Mediated Neurotoxicity, Neuron, vol. 7, 1991, pp 111-118.
Mosinger J. L. et al, Blockade of Both NMDA and Non-NMDA Receptors is Required for Optimal Protection Against Ischemic Neuronal Degeneration in the Vivo Adult Mammalian Retina, Experimental Neurology, vol. 113, 1991, pp 10-17.
Pujol, R et al, Implication of non-NMDA and NMDA receptors in cochlear ischemia, Neuro Report, vol. 3, 1992, pp 200-302.
Reynolds Gavin P, Development in the drug treatment of schizophrenia, TIPS, vol. 13, 1992, pp 116-121.
Sluta K. A. et al, An experimental arthritis model in rats: the effects of NMDA and non-NMDA antagonists on aspartate and glutamate release in the dorsal horn, Neurosc. Letters, vol. 149, 1993, pp 99-102.
Sorrels T. L. et al, Induction of feeding by 7-chlorokynurenic acid, a strychnine-insensitive glycine binding site antagonist, Brain Research, vol. 572, 1992, pp 265-268.
Trullas R et al, Functional antagonists at the NMDA receptor complex exhibit antidepressant actions, European Journal of Pharmacology, vol. 185, 1990, pp 1-10.
Petty Margaret A.
Wettstein Joseph
Zhu Bin
Aventis Pharmaceuticals Inc.
Jones Dwayne C.
Newman Irving
LandOfFree
Use of thiazolobenzoheterocycles for treating multiple... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of thiazolobenzoheterocycles for treating multiple..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of thiazolobenzoheterocycles for treating multiple... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3610363